Study summary

Adding immunotherapy to chemo after surgery cut recurrence in dMMR stage III colon cancer

ATOMIC trial (atezolizumab after surgery) · 712 people, phase 3 · Published March 2026, New England Journal of Medicine

86.3%free of cancer at 3 years, vs 76.2% with FOLFOX alone

What was tested

Atezolizumab plus FOLFOX chemotherapy against FOLFOX alone after surgery for stage III colon cancer with mismatch repair deficiency (dMMR, about 1 in 7 colon cancers).

What they found

What it means

Makes immunotherapy part of treatment after surgery for dMMR stage III colon cancer.

N Engl J Med, via PubMed ↗ Trial record NCT02912559 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.